https://www.biopharmawatch.com/news/SYK/stryker-participate-2026-wells-fargo-healthcare-conference BiopharmaWatch en 2026-09-04T22:32:00.000Z Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/GH/guardant-health-fda-approval-guardant360-cdx BiopharmaWatch en 2026-09-04T22:10:00.000Z Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer https://www.biopharmawatch.com/news/DTC/defence-therapeutics-sharing-agreement-update BiopharmaWatch en 2026-09-04T22:00:00.000Z Defence Therapeutics Provides Updates on Sharing Agreement https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-04T21:05:00.000Z Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/IONS/pelacarsen-phase-3-results-lpahorizon BiopharmaWatch en 2026-09-04T20:41:00.000Z Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) https://www.biopharmawatch.com/news/NVS/novartis-lpa-horizon-phase-iii-results-pelacarsen BiopharmaWatch en 2026-09-04T20:30:00.000Z Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-investor-conferences-2026 BiopharmaWatch en 2026-09-04T20:05:00.000Z Rapid Micro Biosystems to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/NMAD/nomad-power-solutions-special-meeting-adjournment BiopharmaWatch en 2026-09-04T20:05:00.000Z NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS https://www.biopharmawatch.com/news/APMD/apnimed-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-09-04T20:01:00.000Z Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-wells-fargo-conference-2026 BiopharmaWatch en 2026-09-04T20:01:00.000Z Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/INBX/inhibrx-webcast-inbrx-106-phase-2-results BiopharmaWatch en 2026-09-04T20:00:00.000Z Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study https://www.biopharmawatch.com/news/MDT/medtronic-executives-investor-conferences-2026 BiopharmaWatch en 2026-09-04T16:34:00.000Z Medtronic executives to speak at upcoming investor conferences https://www.biopharmawatch.com/news/PLRZ/polyrizon-closes-4-million-offering BiopharmaWatch en 2026-09-04T15:58:00.000Z Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement https://www.biopharmawatch.com/news/TVA/investigation-texas-ventures-acquisition-tva BiopharmaWatch en 2026-09-04T15:22:00.000Z $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Texas Ventures Acquisition III Corp (NASDAQ: TVA) https://www.biopharmawatch.com/news/ORBS/eightco-holdings-portfolio-update-openai-beast-industries BiopharmaWatch en 2026-09-04T15:17:00.000Z Eightco Holdings (NASDAQ: ORBS) rende noto un portafoglio complessivo di circa 380 milioni di dollari, che comprende OpenAI, Beast Industries, oltre 16.000 ETH e quasi 302 milioni di token WLD https://www.biopharmawatch.com/news/PHGE/biomx-zorronet-launches-ai-command-control-platform BiopharmaWatch en 2026-09-04T13:28:00.000Z BiomX: Zorronet Launches No-Code Control Over AI-Powered Autonomous Response Workflows https://www.biopharmawatch.com/news/MMSI/merit-medical-investor-conferences-september-2026 BiopharmaWatch en 2026-09-04T13:25:00.000Z Merit Medical to Participate in Upcoming Investors Conferences in September https://www.biopharmawatch.com/news/LEXX/lexaria-presents-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-04T13:21:24.000Z Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-correction-press-release BiopharmaWatch en 2026-09-04T13:20:00.000Z Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint https://www.biopharmawatch.com/news/IART/integra-lifesciences-presentation-wells-fargo-morgan-stanley-2026 BiopharmaWatch en 2026-09-04T13:15:00.000Z Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference https://www.biopharmawatch.com/news/AKAN/first-towers-fiber-corp-cash-flow-expansion BiopharmaWatch en 2026-09-04T13:05:00.000Z First Towers & Fiber Corp. Delivers First Cash Flow from New 200 KM Fiber Network, Eyes Expansion with Client https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-secures-debt-facility-orbimed BiopharmaWatch en 2026-09-04T12:50:00.000Z Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million https://www.biopharmawatch.com/news/TARS/tarsus-acquisition-alkeus-pharmaceuticals-eye-care BiopharmaWatch en 2026-09-04T12:38:00.000Z Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care https://www.biopharmawatch.com/news/GOSS/gossamer-bio-presentation-cantor-healthcare-conference BiopharmaWatch en 2026-09-04T12:00:00.000Z Gossamer Bio to Present at Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/A/agilent-launch-s540md-slide-scanner-system BiopharmaWatch en 2026-09-04T12:00:00.000Z Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System https://www.biopharmawatch.com/news/SEER/radoff-jec-group-calls-gulyani-resign-seer-board BiopharmaWatch en 2026-09-04T12:00:00.000Z Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.’s Board of Directors https://www.biopharmawatch.com/news/TRLV/trulieve-medical-cannabis-dispensary-dunwoody-georgia BiopharmaWatch en 2026-09-04T12:00:00.000Z Trulieve to Open Medical Cannabis Dispensary in Dunwoody, Georgia https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-conference-call-dabogratinib-results BiopharmaWatch en 2026-09-04T12:00:00.000Z Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-poster-ers-2026-congress BiopharmaWatch en 2026-09-04T12:00:00.000Z Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-04T12:00:00.000Z Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/CMND/clearmind-acquires-charging-robotics-stake BiopharmaWatch en 2026-09-04T11:32:00.000Z Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis https://www.biopharmawatch.com/news/GLAS/glass-house-brands-september-investor-conferences BiopharmaWatch en 2026-09-04T11:30:00.000Z Glass House Brands to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/MGRO/mustgrow-officer-appointment-dsus-grant BiopharmaWatch en 2026-09-04T11:00:00.000Z MustGrow Announces Officer Appointment and Grant of DSUs https://www.biopharmawatch.com/news/BSEM/biostem-technologies-vendaje-access-vizient-premier BiopharmaWatch en 2026-09-04T11:00:00.000Z BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-appoints-raju-willener-cfo BiopharmaWatch en 2026-09-04T11:00:00.000Z VERAXA Biotech Appoints Raju Willener as Chief Financial Officer https://www.biopharmawatch.com/news/TFX/teleflex-dynetic35-stent-cirse-2026 BiopharmaWatch en 2026-09-04T10:30:00.000Z Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026 https://www.biopharmawatch.com/news/IMRN/immuron-launch-proibs-us-market BiopharmaWatch en 2026-09-04T10:00:00.000Z Immuron to launch PROIBS® in the United States https://www.biopharmawatch.com/blog/biotech-companies-by-disease-map-2026 BiopharmaWatch en 2026-09-04T09:22:57.162Z Biotech Companies by Disease: Mapping $672B Across 299 Indications https://www.biopharmawatch.com/news/JAGX/jaguar-health-crofelemer-infant-patient-compassionate-use BiopharmaWatch en 2026-09-04T08:30:00.000Z Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) https://www.biopharmawatch.com/news/MODD/modular-medical-contract-national-pbm-pivot-pump BiopharmaWatch en 2026-09-04T08:00:00.000Z Modular Medical Announces Contract with National U.S. Pharmacy Benefit Manager, Expanding Access to Pivot Tubeless Patch Pump https://www.biopharmawatch.com/news/MODD/modular-medical-webinar-launch-pivot BiopharmaWatch en 2026-09-04T00:00:00.000Z Registration is Now Open for Tribe Public's CEO Presentation and Q&A Webinar Event Titled ''The Road To Revenue: Modular Medical's Strategy For Launching Pivot'' Featuring Modular Medical CEO - Friday, September 4, 2026 https://www.biopharmawatch.com/news/IONS/zanvastro-fda-approval-alexander-disease BiopharmaWatch en 2026-09-03T23:47:00.000Z ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients https://www.biopharmawatch.com/news/BIIB/zorevunersen-dravet-syndrome-eec-2023 BiopharmaWatch en 2026-09-03T23:30:07.000Z Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-biogen-zorevunersen-dravet-syndrome-eec BiopharmaWatch en 2026-09-03T23:30:00.000Z Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)